Evidence map›Paper›PMID 41006211›Full record

ArticleNature communications2025

CD137L promotes immune surveillance in melanoma via HLTF regulation.

Long Liang, Lin Zhu, Xin Li, Wenbin Zhou, Yanbin Zhang, Mien-Chie Hung, Guanxiong Zhang, Yong Chen, Xinwei Kuang, Juan Su and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Long Liang *Department of Dermatology, Xiangya Hospital & School of Life Sciences, Central South University, Changsha, China.
Lin Zhu *Department of Dermatology, Xiangya Hospital & School of Life Sciences, Central South University, Changsha, China.
Xin Li *Medical Genetics & School of Life Sciences, Central South University, Changsha, China.
Wenbin ZhouDepartment of Dermatology, Xiangya Hospital & School of Life Sciences, Central South University, Changsha, China.
Yanbin ZhangMedical Genetics & School of Life Sciences, Central South University, Changsha, China.
Mien-Chie HungGraduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung, China.ORCID http://orcid.org/0000-0003-4317-4740
Guanxiong ZhangDepartment of Dermatology, Xiangya Hospital & School of Life Sciences, Central South University, Changsha, China. guanxiong_zhang@csu.edu.cn.ORCID http://orcid.org/0000-0003-4819-6543
Yong ChenDepartment of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. chenyong@fudan.edu.cn.ORCID http://orcid.org/0000-0002-7188-4566
Xinwei KuangDepartment of Dermatology, Xiangya Hospital & School of Life Sciences, Central South University, Changsha, China. xinweikuang@csu.edu.cn.
Juan SuDepartment of Dermatology, Xiangya Hospital & School of Life Sciences, Central South University, Changsha, China. sujuanderm@csu.edu.cn.
Jing LiuMedical Genetics & School of Life Sciences, Central South University, Changsha, China. liujing2018@csu.edu.cn.
Xiang ChenDepartment of Dermatology, Xiangya Hospital & School of Life Sciences, Central South University, Changsha, China. chenxiangck@126.com.ORCID http://orcid.org/0000-0001-8187-636X
Hong LiuDepartment of Dermatology, Xiangya Hospital & School of Life Sciences, Central South University, Changsha, China. hongliu1014@csu.edu.cn.ORCID http://orcid.org/0000-0001-9976-2985

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82100137
6 · The paper itself

Abstract

Immune checkpoint blockers (ICBs) have demonstrated substantial efficacy across various malignancies, yet the benefits of ICBs are limited to a subset of patients. Therefore, it is essential to identify novel therapeutic targets. By integrating multi-omics data from cohorts of patients with melanoma treated with ICBs, a positive correlation is observed between tumor CD137L expression and the efficacy of PD-1 blockade. Functionally, CD137L induction in cancer cells significantly enhances anti-tumor immunity by promoting CD8

Indexed as

4-1BB LigandImmunologic SurveillanceMelanomaTranscription FactorsAnimalsCD8-Positive T-LymphocytesCell Line, TumorCTLA-4 AntigenFemaleGene Expression Regulation, NeoplasticHumansImmune Checkpoint InhibitorsMicePhosphorylationProgrammed Cell Death 1 Receptor4-1BB LigandCTLA-4 AntigenImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorTNFSF9 protein, humanTranscription Factors

Identifiers

PMID41006211
PMCPMC12475238

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.